### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

### **CURRENT REPORT**

### PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 23, 2020

### CELLECTAR BIOSCIENCES, INC.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

1-36598

(Commission File Number) 04-3321804

(I.R.S. Employer Identification No.)

### 100 Campus Drive, Florham Park, New Jersey 07932

(Address of principal executive offices, and zip code)

(608) 441-8120

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

Genera	l Instruction A.2. below):	, , , , ,			
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				
	e by check mark whether the registrant is an emerging growth company as of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter)		Act of 1933 (17 CFR §230.405 of this chapter) or Rule $\label{eq:main_energy} \text{Emerging growth company } \square$		
accoun	nerging growth company, indicate by check mark if the registrant has elected ting standards provided pursuant to Section 13(a) of the Exchange Act.	ed not to use the extended transition	period for complying with any new or revised financial		
Securit	ies registered pursuant to Section 12(b) of the Act:	T. H. G. L.K.)			
	Title of each class  Common stock, par value \$0.00001	Trading Symbol(s) CLRB	Name of each exchange on which registered NASDAQ Capital Market		
	Warrant to purchase common stock, expiring April 20, 2021	CLRBZ	NASDAQ Capital Market		
ITEM	8.01 OTHER EVENTS				
A copy	cember 23, 2020 we made available an updated Corporate Presentation on to of the Corporate Presentation is attached hereto as Exhibit 99.1 to this Curuke to update this presentation.				
ITEN	4 9.01 FINANCIAL STATEMENTS AND EXHIBITS				
(d) Exh	nibits				
	Number <u>Title</u>				
	99.1 Cellectar Biosciences, Inc. Corporate Presentation,	December 2020			

### SIGNATURE

By: /s/ Dov Elefant

Name: Dov Elefant Title: Chief Financial Officer





NASDAQ: CLRB

### Forward-Looking Statements

This presentation contains forward-looking statements. Such statements are valid only as of today and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experiences and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for CLR 131, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2019 and our Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020.

# 1 Company Overview 2 CLR 131 Clinical Development & Approval Pathway 3 Financials 4 Company Summary and Next Steps

## Company Overview

Developing oncology therapies in rare adult and pediatric orphan and ultra orphan indications

Validated cancer-targeting platform with novel MOA<sup>1</sup>; lead product is CLR 131, a small-molecule radiotherapeutic

Achieved Phase 2 endpoints; CLR 131 demonstrates broad range of efficacy & unique safety profile in B-cell malignancies

Initiated Waldenstrom's macroglobulinemia (WM) pivotal study in Q4 2020; first patient planned enrollment January 2021

Advancing Phase 1 pediatric study in malignant brain tumors, neuroblastoma, and sarcomas

WM Pivotal Study Cost ~\$18M; Incremental \$20M to Study Outcome, \$30M to NDA Submission and \$40M to Approval

### CLR 131 Franchise Strategic Construction

Multiple Pathways to Value Creation

Waldenstrom's macroglobulinemia Pivotal Phase 2b initiated 4Q20; 100% ORR<sup>2</sup> & 83% MRR Multiple Myeloma (MM) 6<sup>th</sup> line of treatment ORR 47%; Patient subset ORR at 40-62%

Clear Registration Pathway in Waldenstrom's macroglobulinemia; Enriching Triple Class Refractory Myeloma Data in Phase 2a Expansion

Accelerated pediatric regulatory pathway; Granted 4 Rare Pediatric Drug designations & ODDs

Opportunity for joint clinical development and commercialization partnerships

CLR 131 Maintains Multiple Clinical Development Pathways; Active Radiotherapeutic Partnership Market Provides Strategic Options

### CLR 131 First to Market Indication

Waldenstrom's macroglobulinemia

- Excellent efficacy and safety profile; extended Treatment Free Survival (TFS)
- 1 WM approved drug & shifting treatment dynamics favor CLR 131
- Ultra-orphan status and CLR 131 Fast Track Designation accelerates registration pathway; study completion 15-18 months
- Clearly defined primary endpoint & achievable study objectives
- Limited clinical and market competitive investment; targeted commercial/medical team sufficient to drive CLR 131 adoption
- Significant topline revenue and favorable NPV in WM; 6% of total market achieves \$1B+ top-line revenue; additional upside likely via compendia listing & 3<sup>rd</sup> party reimbursement for MM

WM Represents an Accelerated Registration Pathway for CLR 131 with Limited Clinical & Commercial Market Competition

# 1 Company Overview 2 CLR 131 Clinical Development & Approval Pathway 3 Financials 4 Company Summary and Next Steps

### CLR 131 - A Phospholipid Ether (PLE) Radio-conjugate


Combination of a Validated Delivery Platform and Therapeutic Payload

- Tumor cells utilize lipids at significantly greater quantities than normal tissue
  - Energy source (β-oxidation)
  - Cell membrane production
  - Signaling molecules
- Cellectar's PLEs exploit inherent tumor cell need for lipids to provide targeted delivery
  - Bind to specialized regions on tumor cells that provide uptake and internalization of lipids
  - Highly conserved across all tumor types
  - Target cancer stem cells, metastasis and primary tumor with same ligand
  - Deliver 20-40% of infused drug to tumor
- CLR 131 a phospholipid radio-conjugate
  - Provides targeted delivery of the radioisotope I-131
  - Phase 2 efficacy and safety in 4 hematologic cancers
  - Pivotal study initiated in WM


### **PLE Tumor Cell Targeting**



**NSCLC SPECT Scan** 



# Waldenstrom's macroglobulinemia Bridges Between NHL<sup>3</sup> & MM FGFR3 Overexpression in B-cell Malignancies and Lipid Rafts



- High level of tyrosine kinase receptors (TKR) = High presence of lipid rafts
- FGFR3 (a TKR) is over expressed in hematologic malignancies
   100% WM 50% Multiple Myeloma ~30% other NHLs
- Images A & B demonstrate a high level of co-localization of FGFR3 & lipid rafts; lipid rafts are not restricted to being only co-localized with FGFR3, in WM there is significant overlap

CLR 131 Response Rates Consistent with Correlation Between Lipid Rafts and Percent FGFR3 Overexpression in Hematologic Malignancies

## Waldenstrom's macroglobulinemia Disease Overview

An Incurable Form of non-Hodgkin's Lymphoma

- Ultra-rare orphan disease
- Incurable disease with significant sequelae<sup>4</sup>
  - Hyperviscosity syndrome
  - Cyroglobulinemia/skin lesions
  - Cold agglutinemia
  - IgM induced peripheral neuropathy
  - Anemia/reduced iron levels
  - Organomegaly lymph nodes, liver, spleen
  - Bing-Neel Syndrome (CNS infiltration)
- ~8-year survival post-initial diagnosis<sup>5,6</sup>
- All patients eventually progress
  - 30-40% within 2 years of initial therapy
- Patients stratified by:
  - Risk levels: High, intermediate and low
  - Gene mutations: MYD88 and CXCR4




# Waldenstrom's macroglobulinemia Patient Journey

No Post-ibrutinib Approved Therapies

Ritux combinations

Ritux + ibrutinib;

SOC since 2019



### Second-line treatments:


- Ibrutinib monotherapy as initial approval
- Chemo-combinations

- Ibrutinib approved in 2015 2<sup>nd</sup> line monotherapy; only FDA approved agent
- Ibrutinib 2<sup>nd</sup> line market penetration 60-80%
- 10-30% of patients do not respond or have suboptimal response to ibrutinib
- 30% of patients discontinue ibrutinib treatment within one year due to toxicities
- Ibrutinib provides no post treatment duration of response (daily dosing required)

**Ibrutinib Only FDA Approved Treatment for WM** 

# WM Risk Profile Impact on Disease Progression

CLR 131 Has Demonstrated Activity in All Risk Profiles and Genotypes



Risk Group	Median Time to Progression	
High Risk	1.9 years	
Intermediate Risk	4.8 years	
Low Risk	9.3 years	

### Four Criteria Determine Risk Profile

- · Bone marrow involvement
- · IgM level
- · Beta2-microglobulin level
- Albumin level


MYD88 Status	Median Time to Progression	
Wild type	1.3 years	
Mutated	5.1 years	

# Waldenstrom's macroglobulinemia Unmet Patient Need Clear Clinical and Market Opportunity for CLR 131

 MYD88<sup>WT</sup>/CXCR4<sup>WT</sup>: No major responses MYD88WT/CXCR4Mut: 70% progress within 2 years BTKi poor efficacy in key genotypes 01 MYD88Mut/CXCR4Mut: Greater major response rates, no complete responses BTKi treated patients with sub-Predicts relapse within 2 years 02 optimal response within 6 months No approved post-ibrutinib therapy Patient suffer atrial fibrillation (high risk of 03 Treatment for BTKi intolerant patients stroke) and significant bleeding events No approved post-ibrutinib therapy 04 Treatment for BTKi patient failures No monotherapy in relapse/refractory setting achieving complete responses BTKi therapy requires treatment until BTKi offers no TFS 05 progression - no treatment free survival (TFS) · All current therapies provide no TFS - no longterm duration of response 60% progress within 2 years of treatment Treatment for high-risk patients 06 Reduced 5-year survival rate 13

### CLR 131 WM Global Pivotal Study Design


Open Label, Single Arm Registration Clinical Study; Rolling Submission



CLR 131 Major Response Rate of 20% Achieves Statistical Significance

# Waldenstrom's macroglobulinemia Disease Assessment

Serum IgM is Primary Biomarker for Response Rate




CLR 131 MRR in 10 of 50 Patients Achieves Pivotal Study Statistical Significance

### CLR 131 Response Rates in WM BTKi Failed<sup>13</sup> Patients

Demonstrates Activity in All Key Genotypes

CLR 131 Responses in BTKi Sub-optimal Response or Failed Patients




- 83% MRR in BTKi sub-optimal response or failed patients
- · First & only monotherapy to achieve a CR in BTKi failed patient population
- · Only treatment tested in BTKi failure patients

CLR 131 Only Monotherapy to Achieve 83% MRR and a CR in BTKi Failed or Sub-optimal Response Patients

\* Patient's efficacy assessment ongoing

### CLR 131 Treatment Free Survival in WM BTKi Failed Patients

Meaningful TFS Exhibited



- Initial response for most patients occurs within 22 days of first cycle
- Time to major response is typically less than 45 days
- Ibrutinib provides no TFS; progression within 4 weeks after treatment discontinuation

CLR 131 Treatment Free Survival 330 Days on Average and Ongoing For All Patients; No Patients Have Initiated New Therapy

### **WM Major Response Rates**

CLR 131 Exceeds All Reported MRRs (Overall and by Subtype)

Drug	Overall	Prior BTKi exposure	MYD88 <sup>MUT</sup> / CXCR4 <sup>WT</sup>	MYD88 <sup>MUT</sup> / CXCR4 <sup>MUT</sup>	MYD88 <sup>W™</sup> / CXCR4 <sup>MU™</sup>	MYD88 <sup>WT</sup> / CXCR4 <sup>WT</sup>
Ibrutinib 11,12 (n=63)	78%	N/A	91.2%	61.9%	NR	0%
Acalabrutinib (n=92)	78%	NT	NR	NR	NR	NR
Zanubrutinib (n=73)	78%	NT	59%	27.3%	NT	11%
Venetoclax (n=30)	73%	30% (n=10)	86%	63%	NT	NT


- · All BTKi's evaluated in treatment naïve and post first line relapsed patients
  - Non-reversible and reversible BTKi behave the same in WM
  - Neither provide meaningful responses in the difficult to treat MYD88 wild type patients
- Venetoclax evaluated in treatment naïve and post first line relapsed patients
  - 10 patients were BTKi previously treated; demonstrated 30% response rate
  - Based upon genotypes, most patients expected to be BTKi intolerant
  - Based upon intolerant rates to ibrutinib, 50% (n=5) of patients likely intolerant

Currently MRR in BTKi Failures or Sub-optimal Response 15-24%


# Waldenstrom's macroglobulinemia Global Market

Epidemiology and Treatment Centers by Region






### Annual Prevalence ~60,0007



### **Key Treatment Centers 70**



- · Median age at diagnosis is 65
- · 5-year survival for high-risk patients @ 36%
- U.S. represents a slightly larger market opportunity with a higher prevalence
- · More common in males of European descent
- · Growth rate driven by aging population

Incidence Growth Rate of ~30% Through 2025

# Waldenstrom's macroglobulinemia Global Market

CLR 131 Forecasted Revenue in 2<sup>nd</sup> & 3<sup>rd</sup> Line Patient Population



Assumptions	Factor
2 <sup>nd</sup> /3 <sup>rd</sup> Line Population	6,008
Annual Growth Rate	2.33%
Revenue Per Dose	\$75,000
Avg. Revenue Per Patient	\$262,500
Market Ramp to Peak Penetration	6 Years

- Global WM prevalence ~60,000; forecasted 2<sup>nd</sup>/3<sup>rd</sup> line market shares of 30%, 55% & 80% represent ~ 3%, 6% & 8% of overall prevalence market
- Projection are global revenues (U.S. represents ~60% of global market)
- Patent protection and regulatory exclusivity until 2032/2033

Forecasted WM Peak Revenue ~\$670M - >\$1.8B

# CLR 131 For The Treatment Of Multiple Myeloma Challenging Patient Population - Characteristics 14


Criteria	Total Body Dose <50 mCi (n=11)	Total Body Dose ~50 mCi (n=22)	Total Body Dose ≥60 mCi (n=20)	Total (n=53)
Median Age (Min-Max)	68.5 (55-85)	70 (51-82)	70 (59-83)	70 (51-85)
Male (%)	50	60	71	62
Median Prior Lines of Therapy (Min-Max)	4 (3-12)	5 (2-13)	5 (3-17)	5 (2-17)
Cytogenetics at Diagnosis				
High Risk [n (%)]	3 (27.2)	8 (36.4)	8 (40)	19 (35.8)
Unknown [n (%)]	0	3 (15)	4 (18)	7 (13.2)
Median Beta-2 Macroglobulin (Range)	2.62 (2.09,4.4)	3.9 (1.98,9.49)	2.65 (1.1,4.4)	2.83 (1.1, 9.49)

Total Evaluable Patients n=49 (%)			
Refractory to Immediate Prior Therapy 44 (89.8)			
Quad <sup>15</sup> /penta-refractory <sup>16</sup> 31 (63.3)			
Triple Class Refractory <sup>17</sup>	26 (53.1)	25 (96.2)	

**Patient Population Mirrors Real World Utilization** 

## Multiple Myeloma Competitive Landscape

Approved Products and CLR 131 Response Rate Summary



- ORR for on-market drugs 22.9% to 31%
- Only two approved drugs with triple class refractory response data
  - Selinexor (25.4%) and belantamab (31%)

**CLR 131 Demonstrates Activity in Key Refractory Patient Populations** 

# CLR 131 All B-cell Malignancies Patients

Well Tolerated Safety Profile in WM, MM and Other NHL's

# Treatment Emergent Adverse Events<sup>14</sup> (≥25% of All Patients)

(=25% of All Facility)			
	Total r	ALL DOSES Total n = 88 Phase 1 & 2 Pts	
Preferred Term	Overall n (%)	≥ Grade 3 n (%)	
Thrombocytopenia	73 (83)	64 (73)	
Lymphocyte count decreased	40 (45)	35 (40)	
Decreased White Blood Cell Count	52 (59)	41 (47)	
Anemia	60 (68)	15 (17)	
Neutropenia	49 (56)	45 (51)	
Fatigue	51 (60)	12 (14)	
Nausea	29 (33)	0	

- Most frequent TEAEs<sup>19</sup> are cytopenias; very predictable and manageable
  - Nadir occurs ~34 days post initial dose; recovery occurs within ~21 days post nadir
- · No deaths, cardiotoxicities, liver, renal or neurologic toxicities, keratopathy, etc.

# 1 Company Overview 2 CLR 131 Clinical Development & Approval Pathway 3 Financials 4 Company Summary and Next Steps

## **Financials**

### Capitalization as of November 9, 2020

Common Stock Outstanding	26,813,593
--------------------------	------------

Reserved for issuance:

Convertible Preferred Stock <sup>20</sup>	537,500
Warrants	17,937,766
Employee/Director Stock Options	1,184,464

Fully Diluted 46,473,323

Cash/Equivalents as of September 30 ~\$18.8 million

WM Pivotal Study Cost ~\$18M; Incremental \$20M to Study Outcome, \$30M to NDA Submission and \$40M to Approval

# 1 Company Overview 2 CLR 131 Clinical Development & Approval Pathway 3 Financials 4 Company Summary and Next Steps

### **Company Summary**

### CLR 131 Clinical Development Next Steps

- High unmet medical need and significant market opportunity in Waldenstrom's macroglobulinemia and Multiple Myeloma
  - WM: BTKi (ibrutinib) failed patients
  - MM: Subset populations: Later line, triple class & quad/penta refractory
- CLR 131 impressive product profile in B-cell malignancies
  - WM: 100% ORR & 83.3% MRR in BTKi failed patients; extended TFS
  - MM: 47% ORR 6<sup>th</sup> line, 40% triple class and 54% quad/penta refractory
- Near-term clinical development plan
  - WM: Phase 2b pivotal study initiated 4Q20
  - MM: Phase 2a to enroll additional ~15 triple class refractory patients
  - Pediatric: Phase 1 malignant brain tumors, neuroblastoma & sarcomas

CLR 131 is an Effective Drug in Multiple Indications; Lead Indication WM represents an Underserved and Addressable Market





NASDAQ: CLRB

### **Footnotes**

- 1. Mechanism of Action
- 2. Overall Response Rate
- 3. Non-Hodgkin's Lymphoma
- 4. https://www.iwmf.com/about-wm/signs-and-symptoms
- 5. Sekhar J, et.al.. Waldenström macroglobulinemia: a SEER database review from 1988 to 2005. Leuk Lymphoma 2012;53(8):1625-1626;
- 6. https://www.orpha.net/consor/cgi-bin/OC Exp.php?Expert=33226
- 7. Datamonitor Healthcare; Centers for Disease Control and Prevention, 2017; Ferlay et al., 2018; National Cancer Institute, 2017; Steingrímsson et al., 2017; United Nations, 2017
- 8. Treon et al. 2012. New England Journal of Medicine. 367, 826-833.
- 9. Hunter et al. 2014. Blood. 123, 1637-1646.
- 10. Castillo and Treon, Leukemia, 2019.
- 11. Treon et al, EHA 2018
- 12. Treon et al, EHA 2018
- 13. Failed = patient achieving less than a partial response including disease progression
- 14. Data as of 31Jan2020
- 15. When patients are refractory to 4 therapeutic agents
- 16. When patients are refractory to 5 therapeutic agents
- 17. When patients are class refractory to proteasome inhibitor, Immunomodulatory drug, and CD38 antibodies
- 18. ODAC Briefing Document, Selinexor Feb. 26, 2019. ; Usmani, et al (2016). Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood Journal. ; Dimopolous et al (2016). Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory [MM]. Blood Review. ; Jurczyszyn et al (2014). New drugs in multiple myeloma role of carfilzomib and pomalidomide. Contemporary Oncology; Lancet Oncology DREAMM-2 Study 2.4 mg per kg; KarMMa-2 Study Dose group 300x106
- 19. Treatment Emergent Adverse Events
- 20. Convertible preferred stock is convertible at any time at the holder's option into a number of shares of common stock at a conversion rate of 1:2,500. There are currently 215 shares outstanding they do not contain any preferential rights over common stock

# **Executive Leadership**

Jim Caruso
President, CEO and Director

HIP Innovation Technology -Co-Founder, EVP & COO, Allos Therapeutics - EVP & CCO, BCI, Novartis, BASF, Bristol-Myers Squibb





Dov Elefant Chief Financial Officer Akari Therapeutics PLC - CFO, Celsus Therapeutics, Inc. - CFO Lev Pharmaceuticals - Corporate Controller





John Friend, MD Chief Medical Officer DRGT - CMO, Helsinn Therapeutics -SVP & Head of R&D, Akros Pharma, Actavis, Alpharma, Hospira, Abbott





Jarrod Longcor Chief Business Officer Avillion LLP - CBO
Melinta Therapeutics, Inc. (formerly
Rib-X Pharmaceuticals, Inc). - VP Corp
Development and Operations





Executive Team With Extensive Healthcare Leadership and a Proven Track Record of Product Development and Commercialization

# Waldenstrom's macroglobulinemia Disease Manifestation

MYD88 and CXCR4 Genotypes Drive Disease and Outcomes

